Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Index by author

October 1, 2016; Volume 57,Issue 10

Cover image

Cover image expansion

A 211At-labeled small molecule developed to target PSMA has been shown to yield specific cell killing and improved survival in mice bearing prostate cancer micrometastases. See page 1569.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 57 (10)
Journal of Nuclear Medicine
Vol. 57, Issue 10
October 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Molecular Imaging of Immunotherapy Targets in Cancer
  • 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer
  • A Continuously Infused Microfluidic Radioassay System for the Characterization of Cellular Pharmacokinetics
  • Radionuclide Evaluation of Brain Death in the Post-McMath Era
Sign up for alerts

Jump to

  • This Month in JNM
  • SNMMI Newsline
  • Focus on Molecular Imaging
  • Invited Perspectives
  • Clinical Investigations
  • Brief Communications
  • Continuing Education
  • Basic Science Investigations
  • Brief Communications
  • Special Contributions
  • Letters to the Editor
  • Most Cited
  • Most Read
Loading
  • Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
  • Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
  • 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
  • Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
  • Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire